Recon: Danaher to purchase Masimo for $9.9B; EU authorizes higher dose of Novo’s Wegovy

• FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher (Endpoints)
• Disc Medicine eyes standard US approval for drug after FDA denies fast-track nod (Reuters )
• Act For ALS Boosted Drug Access, But Rollout Faced Initial Hurdles, GAO Says (Pink Sheet)
• Rare Disease Month Developments, Part 1 – The Good: RPD PRV Program Renewed, FDA Rare Disease Hub’s 2026 Strategic Agenda & Plausible Mechanism Draft Guidance On Its Way (FDA Law Blog)
• CDC Left Leaderless Again After Acting Director Departs HHS (BioSpace) (Reuters)

• As China’s drug industry races ahead, its GLP-1 race is accelerating too (STAT)
• Lilly targets India as global export hub amid booming Mounjaro sales (Reuters)
• EU approves higher dose of Novo Nordisk's Wegovy (Reuters)
• Dr Reddy’s says Wegovy copycat to be priced competitively, with 50–60% discounts feasible (Reuters)
• Obesity Drug Boom Buoys Ireland’s Pharma Production for Export (Bloomberg)
• Elevidys Becomes Japan’s Highest-Priced Drug Nine Months After Approval (Pink Sheet)
• Time for Innovative Medicines Fund 2.0 in England: Industry and Patients Want Change (Pink Sheet)

• Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial (STAT)
• Compass says its psilocybin drug helped patients with severe depression in two trials (STAT)
• Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy (Endpoints)
• Roche heads to regulators with new autoimmune win for Gazyva (Fierce Pharma)
• ‘Hypertension Bites’: AZ-backed coalition launches ’90s-inspired awareness campaign (Fierce Pharma)
• Lilly's rare cancer drug Retevmo looks to broaden reach with adjuvant trial win (Fierce Pharma)

• Danaher to buy Masimo in $9.9 billion deal in diagnostics push (Reuters)
• Medtronic completes first Hugo case in the US (MedTech Dive)
• Medline Recalls Beds After Reports Of Injuries and Deaths Due To Fire, Entrapment (MedTech Insight)
• NASA’s Former AI Chief Omar Hatamleh: AGI Is Closer Than We Think, Then Everything Will Change (MedTech Insight)

• A Life-Saving Vitamin for Babies Is Getting Swept Up in Vaccine Backlash (Bloomberg)
• Familiar faces: Why food and beverage companies are bringing back former CEOs (Food Dive)

• In a financial pinch, major health insurers are turning to AI for help (STAT)
• When IV opioids are in short supply at the hospital, who gets pain relief? (STAT)
• AMA CEO: Deepfake doctors are a threat to public health (STAT)
• Bayer proposes $10.25 billion plan for all Roundup cancer cases (Reuters)